The Formosa Plastics Group established the "Formosa Plastics Health and Lifestyle Pavilion" at the "Taiwan Medical Technology Exhibition" that debuted today.

(Photo by reporter Chen Yongji)

[Reporter Chen Yongji/Taipei Report] Formosa Plastics Biomedical invested NT$755 million in July this year to acquire a 51% stake in "Ivy Life Sciences Company". The rich experience in the development of therapeutic clinical application technology is expected to accelerate research and development, reduce costs, and further expand more indications.

Formosa Plastics Group announced its achievements in the biomedical industry in the past year at the "Taiwan Medical Technology Exhibition".

Among them, the layout of Formosa Plastics Biomedical in the field of regenerative medicine has attracted the most attention.

Liu Huiqi, general manager of Formosa Plastics Biomedical and deputy director of Changchun Teng, said that the core technology of Changchun Teng Life Sciences is "CIK autoimmune killer cell medical technology" (the product name is IKC for short), which is a kind of autoimmune cells that rapidly proliferate in vitro , and then reinfused into the patient's body to improve its own immune function, anti-cancer activity of immune cells, and a medical technology that improves the quality of life.

Please read on...

Liu Huiqi pointed out that the CIK cell therapy product cultivated by the Ivy IKC technology has not only completed the first phase of clinical human trials for the treatment of advanced liver and lung cancer, and verified its safety; The first clinical phase II human trial in Taiwan to use immune cells to treat stage IV non-small cell lung cancer. The effectiveness has been proven. If the Legislative Yuan can successfully pass the dual laws of regenerative medicine in the first quarter of next year, it will be of great help to Ivy’s business .

At present, 9 hospitals including 6 medical centers in the country have entrusted Ivy Life Sciences to prepare cells to implement the clinical business of cell therapy under special management methods, and the treatment targets include patients with solid cancer and hematological malignancies.

In the future, more medical institutions will be approved to use Ivy Life Science's cell preparations.

It is suitable for cancer patients with specially managed cell therapy. It can also be treated simultaneously with traditional chemotherapy, radiotherapy, surgery or immune cell drugs to reduce the discomfort and side effects caused by traditional treatment and improve the efficacy of treatment. There are new options for cancer treatment, and you can get the most appropriate treatment.

Grasp the pulse of the economy with one hand I subscribe to Free Finance Youtube channel

Already added friends, thank you

Welcome to 【Free Finance】

feel good

Already liked it, thank you.

related news